Journal
ACTA NEUROLOGICA SCANDINAVICA
Volume 119, Issue 4, Pages 239-245Publisher
WILEY-BLACKWELL
DOI: 10.1111/j.1600-0404.2008.01090.x
Keywords
CD25; cytokines; Foxp3; glucocorticoids; methylprednisolone; multiple sclerosis; regulatory T cells
Categories
Funding
- NCI NIH HHS [P30 CA010815] Funding Source: Medline
- NCRR NIH HHS [S10 RR024693] Funding Source: Medline
Ask authors/readers for more resources
To determine whether percentages of CD4(+)CD25(high) T cells (a group of regulatory T cells, Treg) differ in patients with multiple sclerosis (MS) in relapse vs remission after glucocorticoid treatment and whether treatment for relapses changes Treg population and the expression of Foxp3, a key Treg-associated molecule. Peripheral blood mononuclear cells (PBMC) were obtained from 20 patients with MS during relapse, just before and 2 days after starting steroid treatment (i.v. methylprednisolone 1 g/day for 3 days) and then 6 weeks after treatment. CD4(+)CD25(hi) cells were analysed by using flow cytometry. Cytokines were measured by using an ELISA and Foxp3, CD3 and CD25 expression by using quantitative real-time PCR. The percentage of CD4(+)CD25(hi) cells, plasma IL-10 and Foxp3/CD3 ratio increased 48 h after methylprednisolone initiation and returned to baseline values by 6 weeks post-treatment. Results suggest that glucocorticoids increase Treg cell functional molecules and percentages. This may be a mechanism whereby steroids expedite recovery from MS relapses.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available